2019
DOI: 10.1111/cbdd.13484
|View full text |Cite
|
Sign up to set email alerts
|

Plasmodium falciparum: Multidrug resistance

Abstract: Malaria is the most lethal and debilitating disease caused by the protozoan parasite Plasmodium worldwide. The most severe forms of disease and the incidence rates of mortality are associated with P. falciparum infections. With the identification of disease source and symptoms, many chemical entities were developed naturally and synthetically for administration as a potential antimalarial drug. The major classes of approved antimalarial drugs that are governed as first‐line treatment in tropical and subtropica… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
31
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 44 publications
(31 citation statements)
references
References 98 publications
(484 reference statements)
0
31
0
Order By: Relevance
“…Malaria remains an important global health concern as effective vaccines are unavailable and acquired resistance to approved drugs may undermine progress made in the last two decades [1]. As much of the recent progress is attributed to mosquito control [2], increasing rates of insecticide resistance in these disease vectors is also worrisome for achieving the goal of malaria eradication [3].…”
Section: Introductionmentioning
confidence: 99%
“…Malaria remains an important global health concern as effective vaccines are unavailable and acquired resistance to approved drugs may undermine progress made in the last two decades [1]. As much of the recent progress is attributed to mosquito control [2], increasing rates of insecticide resistance in these disease vectors is also worrisome for achieving the goal of malaria eradication [3].…”
Section: Introductionmentioning
confidence: 99%
“…[ 5,6 ] Despite tremendous progress, the efficacy of ARTs is being increasingly jeopardized by the emergence and spread of P. falciparum strains that are resistant to artemisinin derivatives and to their partner drugs, as evidenced by the fact that no significant progress in reducing global malaria cases was made from 2015 to 2017, endangering the future efficacy of ACTs. [ 7,8 ] Thus, it is urgent to develop new antidotes against malaria, especially drug‐resistant malaria.…”
Section: Introductionmentioning
confidence: 99%
“…The increase in global drug resistance in the malaria-endemic areas has significantly reduced the potency of most current used antimalarial compounds. In order to solve this problem, the development of new antimalarial drug candidates with novel potential mechanisms of action is urgently needed [7][8][9][10] . Efforts to discover new 4-aminoquinoline derivatives are ongoing.…”
Section: Introductionmentioning
confidence: 99%